Suppr超能文献

治疗前血清乳酸脱氢酶作为小细胞肺癌患者的额外分期参数

Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma.

作者信息

Stokkel M P, van Eck-Smit B L, Zwinderman A H, Willems L N, Pauwels E K

机构信息

Department of Diagnostic Radiology and Nuclear Medicine, Leiden University Medical Centre, The Netherlands.

出版信息

J Cancer Res Clin Oncol. 1998;124(3-4):215-9. doi: 10.1007/s004320050157.

Abstract

PURPOSE

At present the standard staging procedure in patients with small-cell lung cancer (SCLC) is extensive, expensive and time-consuming. Furthermore, the predictive and prognostic value of the current staging system is poor. To determine the value of pretreatment clinical and biochemical parameters to predict tumour stage and to assess prognosis, a retrospective study was performed of 121 consecutive patients with newly diagnosed SCLC.

METHODS

On the basis of routine diagnostic procedures, 51 patients were staged as having limited disease and 70 patients as having extensive disease. During follow-up, data on tumour progression and survival were gathered. These data and the tumour stage were correlated with lactate dehydrogenase (LDH), alkaline phosphatase, liver enzymes, leucocyte count, protein, albumin, calcium, age and gender.

RESULTS

Follow-up ranged from 1 week to 96 months, during which 110 patients died. In all patients with LDH levels above 400 U/l (n = 31), metastases were found at the initial stage, whereas all patients initially staged as having limited disease and LDH levels above 240 U/l showed tumour progression. Bone and liver were found to be the most commonly involved sites, whereas the incidence of brain metastases increased during follow-up. In patients initially staged as having limited disease, no differences in survival were found between those showing local recurrence and those developing metastases during follow-up (P = 0.67). Compared to the patients initially staged as having extensive disease, the survival of both groups was significantly better (P < 0.001). Significant independent variables of survival were LDH, albumin, initial stage and gender, but LDH was the best overall predictor (P < 0.001).

CONCLUSION

These results suggest that pretreatment LDH may be used as an additional staging parameter in SCLC, which can identify prognostic subgroups before treatment.

摘要

目的

目前,小细胞肺癌(SCLC)患者的标准分期程序繁杂、费用高昂且耗时。此外,当前分期系统的预测和预后价值较差。为了确定治疗前临床和生化参数对预测肿瘤分期及评估预后的价值,对121例新诊断的连续性SCLC患者进行了一项回顾性研究。

方法

根据常规诊断程序,51例患者被分期为疾病局限型,70例患者为疾病广泛型。在随访期间,收集了肿瘤进展和生存数据。这些数据以及肿瘤分期与乳酸脱氢酶(LDH)、碱性磷酸酶、肝酶、白细胞计数、蛋白质、白蛋白、钙、年龄和性别进行了相关性分析。

结果

随访时间为1周至96个月,期间110例患者死亡。在所有LDH水平高于400 U/L的患者(n = 31)中,初始阶段即发现有转移,而所有初始分期为疾病局限型且LDH水平高于240 U/L的患者均出现肿瘤进展。发现骨和肝是最常受累的部位,而脑转移的发生率在随访期间有所增加。在初始分期为疾病局限型的患者中,随访期间出现局部复发和发生转移的患者之间生存率无差异(P = 0.67)。与初始分期为疾病广泛型的患者相比,这两组患者的生存率均显著更高(P < 0.001)。生存的显著独立变量为LDH、白蛋白、初始分期和性别,但LDH是总体最佳预测指标(P < 0.001)。

结论

这些结果表明,治疗前LDH可作为SCLC的一个额外分期参数,能够在治疗前识别预后亚组。

相似文献

4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

引用本文的文献

7
Prognostic factors in patients with small cell lung carcinoma.小细胞肺癌患者的预后因素。
Med Oncol. 2010 Jun;27(2):237-41. doi: 10.1007/s12032-009-9198-8. Epub 2009 Apr 28.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验